home / stock / avtx / avtx quote
Last: | $12.7781 |
---|---|
Change Percent: | -3.27% |
Open: | $12.9191 |
Close: | $12.7781 |
High: | $13 |
Low: | $12.39 |
Volume: | 3,777 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$12.7781 | $12.9191 | $12.7781 | $13 | $12.39 | 3,777 | 07-19-2024 |
$12.51 | $12 | $12.51 | $13 | $12 | 2,916 | 07-18-2024 |
$12.9809 | $12.0172 | $12.9809 | $13.19 | $12.0172 | 11,040 | 07-17-2024 |
$12.5 | $12.49 | $12.5 | $12.6 | $12.35 | 4,480 | 07-16-2024 |
$12.65 | $12.185 | $12.65 | $12.75 | $11.74 | 14,307 | 07-15-2024 |
$12.16 | $12.51 | $12.16 | $12.51 | $11.7399 | 2,443 | 07-12-2024 |
$12 | $12.31 | $12 | $12.625 | $12 | 54,381 | 07-11-2024 |
$12.545 | $12.35 | $12.545 | $12.8999 | $12.35 | 3,812 | 07-10-2024 |
$12.86 | $12.605 | $12.86 | $13.3 | $12.5547 | 4,663 | 07-09-2024 |
$13.15 | $12.75 | $13.15 | $13.23 | $12.575 | 7,832 | 07-08-2024 |
$12.59 | $11.24 | $12.59 | $12.99 | $10.99 | 19,420 | 07-05-2024 |
$11.64 | $11.75 | $11.64 | $12.1 | $11.6078 | 3,006 | 07-04-2024 |
$11.64 | $11.75 | $11.64 | $12.1 | $11.6078 | 3,006 | 07-03-2024 |
$12.26 | $12.3 | $12.26 | $12.98 | $12.09 | 4,241 | 07-02-2024 |
$12.61 | $12.13 | $12.61 | $13.0151 | $11.34 | 12,944 | 07-01-2024 |
$12.47 | $13 | $12.47 | $13.13 | $12.47 | 10,116 | 06-28-2024 |
$13.2 | $13.16 | $13.2 | $13.6 | $13.125 | 18,460 | 06-27-2024 |
$13.04 | $13.87 | $13.04 | $13.87 | $13.04 | 5,411 | 06-26-2024 |
$13.895 | $13.43 | $13.895 | $13.9592 | $12.28 | 7,987 | 06-25-2024 |
$13.43 | $12.87 | $13.43 | $13.9999 | $12.482 | 15,552 | 06-24-2024 |
News, Short Squeeze, Breakout and More Instantly...
Avalo Therapeutics Inc. Company Name:
AVTX Stock Symbol:
NASDAQ Market:
Avalo Therapeutics Inc. Website:
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. “We are thrilled to have Mittie join and grow our leadership team at an exciting...
Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Ava...
2024-07-06 21:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...